Last year, it wasn’t even in the Top 10. This year, they’re number one. General Motors was ranked as the most China-exposed U.S. multinational by Strategy Risks, a political risk consultancy in New York.
CPA strongly endorses the FEOC Excise Tax in the Senate reconciliation bill as a critical step in protecting America’s solar manufacturing industry from reliance on subsidized and compromised Chinese components.
The U.S. kitchen cabinet industry has a long and storied history, deeply rooted in small- to medium-sized businesses that form the backbone of American manufacturing.
CPA warned that the Senate version of President Trump’s reconciliation bill—known as the One Big Beautiful Bill—contains a critical loophole in both the Section 48E investment tax credit and 45Y production tax credit in the Inflation Reduction Act (IRA), creating an unintended but dangerous giveaway to China’s solar industry.
The two Trump Administrations have reshaped the debate on U.S. trade policy. For the first time in decades, U.S. officials are no longer endorsing the “free trade” orthodoxy that has contributed to the erosion of its manufacturing sector. Instead, tariffs are now the centerpiece of U.S. plans to repatriate supply chains and reindustrialize America.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
A newly released report from the Congressional Budget Office (CBO) has upended the way policymakers should think about tariffs.
In the U.S. today, frontline cancer treatments are being rationed. ERs are short on sedatives. Amoxicillin—one of the most prescribed antibiotics in the country—has been in critical shortage. These are not temporary disruptions. They reflect a structural breakdown caused by the erosion of America’s pharmaceutical manufacturing base and a decades-long surge in generic drug imports.
Treasury Secretary Scott Bessent stepped into somewhat hostile territory in the Senate Finance Committee hearing on Thursday. But despite dramatic criticism from Ranking Member Ron Wyden (D-OR) and other top Democrats on the Committee, Bessent took an early victory lap on tariffs.
U.S. based generic drug makers need government support to expand – and maybe even to survive – the onslaught of imports nearly every member of the House Energy and Commerce Committee Subcommittee on Health said in a hearing on Wednesday.
